Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Trovagene and Barretos Cancer Hospital, Brazil, to Evaluate Urine-Based HPV Assay

Published: Wednesday, November 28, 2012
Last Updated: Wednesday, November 28, 2012
Bookmark and Share
The goal of the study is to determine whether this assay can potentially replace Pap smears as the primary screen for cervical cancer risk in Brazil’s healthcare system.

Trovagene, Inc. and the PIO XII Foundation, affiliated with Brazil’s Barretos Cancer Hospital, today announced that they entered into a research collaboration to evaluate the performance of a urine-based molecular assay for detection of HPV types associated with cervical lesions. The goal of the study is to determine whether this assay can potentially replace Pap smears as the primary screen for cervical cancer risk in Brazil’s healthcare system. Barretos Cancer Hospital, Brazil’s preeminent center for oncology research and cancer treatment, will conduct the study using Trovagene’s proprietary, urine-based method for determining the presence of high risk HPV types, allowing for completely non-invasive HPV carrier screening.
 
HPV infections are the leading cause of cervical cancer. In medically underserved regions, traditional screening methods to detect elevated risk of cervical cancer, such as a Pap smear, are not broadly available. In Brazil, cervical cancer is the second most frequent tumor type in women and the leading cause of cancer-related mortality in women 14 to 44 years of age. Brazil has placed special emphasis on programs to improve HPV screening to address this pressing healthcare need.
 
"We are excited to begin this important clinical trial using Trovagene’s proprietary urine-based HPV assay," says Adhemar Longatto Filho, M.Sc., Ph.D., PMIAC, from the Laboratory of Medical Investigation at the University of Sao Paulo and principal investigator for the study at Barretos Cancer Hospital. "This study can pave the way to make HPV screening broadly available to medically underserved patients in our region. Our goal is to provide patients with non-invasive testing options to determine their HPV risk factor and significantly improve women’s healthcare in Brazil."
 
"We are committed to work with Barretos Cancer Hospital to study the performance of our proprietary HPV assay in Brazil. Improved logistics, reduced costs and increased compliance can significantly increase HPV screening rates and save lives," states Antonius Schuh, Ph.D., chief executive officer of Trovagene. “This collaboration with Barretos is another important step towards making Trovagene’s non-invasive HPV carrier screen available in key healthcare markets globally.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Stephen Zaniboni Joins Trovagene, Inc. as Chief Financial Officer
Mr. Zaniboni's experience includes raising more than $500 million through venture financing and IPO proceeds.
Friday, February 10, 2012
Scientific News
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
Harnessing Nature’s Vast Array of Venoms for Drug Discovery
Scripps scientists have developed a method for rapidly identifying venoms.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
The Need for Speed
Evaluating MALDI-TOF as a high-throughput screening technology for the pharmaceutical industry.
Antarctic Sponge Extract Kills MRSA
New findings may provide opportunity for developing new drugs to fight dangerous bacteria currently highly resistant to treatment.
US-India Collab Finds Molecular Signatures of Severe Malaria
Study may be a significant advancement in understanding the causes of severe malaria.
Novel Way to Prevent Deadly Bacterial Infections
Monash scientists may have found a way to stop deadly bacteria from infecting patients. The discovery could lead to a whole new way of treating antibiotic-resistant “superbugs”
Gene Expression Controls Revealed
Researchers have modelled every atom in a key part of the process for switching on genes, revealing a whole new area for potential drug targets.
An Old-New Weapon Against Emerging Chikungunya Virus
Researchers utilize existing drugs to interfere with host factors required for replication of Chikungunya virus.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!